Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

entation, subgroup analyses from the SPIRIT III trial demonstrated evidence of the strong performance by XIENCE V in a variety of patients and lesion types that represent complex patients. In patients with diabetes, the analysis showed there was no difference at three years in MACE between XIENCE V and TAXUS (11.0 percent for XIENCE V vs. 10.3 percent in TAXUS)*** . In fact, XIENCE V maintained a consistent rate of clinical events after the first year (8.7 percent MACE at one year and 11.0 percent MACE at three years), whereas TAXUS demonstrated a sustained upward trend in clinical events from one year to three years (4.7 percent MACE at one year and 10.3 percent MACE at three years). In patients without diabetes, the MACE rate for TAXUS at three years was more than double the MACE rate for XIENCE V at three years (9.1 percent for XIENCE V vs. 18.7 percent for TAXUS).

"The SPIRIT III data clearly show that XIENCE V performs in a consistent manner, with clinical benefits continuing to improve over time compared to TAXUS," said Robert Hance, senior vice president, vascular, Abbott. "We are pleased to begin this year's TCT conference with a strong showing of data for Abbott's market-leading XIENCE V, and look forward to presenting the highly anticipated SPIRIT IV one-year results later this week, which should provide physicians with additional valuable insights."

One-year results from the company's SPIRIT IV trial will be presented on Wednesday, Sept. 23, during the first late-breaking clinical trials session of the TCT conference. The SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents, with 3,690 patients enrolled, including more than 1,000 patients with diabetes. The study results will provide valuable information about the efficacy and safety of XIENCE V compared to TAXUS. The SPIRIT III trial was not designed to analyze statistical differences in any of the patient subgroups, as th
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 A drug commonly taken to prevent seizures ... multiple sclerosis (MS), according to a study released today that ... Annual Meeting in Washington, DC , April ... people with MS experience at some point in their life ... carrying vision from the eye to the brain gets inflamed," ...
(Date:4/16/2015)...  Amgen (NASDAQ: AMGN ) today announced that ... Tuesday, April 21, 2015, after the close of the ... a conference call with the investment community at 2 ... be Robert A. Bradway , chairman and chief ... team. Live audio of the conference call ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
Breaking Medicine Technology:Epilepsy Drug May Preserve Eyesight for People with MS 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Diplomat Names Shannon M. Beltrand as New CISO 2
... TEMECULA, Calif., Nov. 17 Patient Safety Technologies, Inc. ... results. , "We are continuing to see strong year ... margins," stated Steven H. Kane, Chief Executive Officer of ... sales of safety sponges were comparable with revenues in ...
... WebMD Health Corp. (Nasdaq: WBMD ) today announced that executives ... Research Small and Mid Cap Conference on Friday, November 20, 2009 ... general public are invited to listen to a live audio broadcast ... accessed at www.wbmd.com (in the Investor Relations ...
Cached Medicine Technology:Patient Safety Technologies Reports Third Quarter Results 2Patient Safety Technologies Reports Third Quarter Results 3Patient Safety Technologies Reports Third Quarter Results 4Patient Safety Technologies Reports Third Quarter Results 5Patient Safety Technologies Reports Third Quarter Results 6
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. ... of platelet-rich plasma (PRP) and stem cell ... known for its world-class care of injury-caused and chronic ... lacking in many other physicians offering regenerative medicines. ... for pain management and rehabilitation. Dr. Meier and MOSM ...
(Date:4/17/2015)... Tallahassee, Fla. (PRWEB) April 17, 2015 ... percent of dental restoration units are made overseas by ... Commission. Additionally, domestic labs remain unregulated in more than ... , The National Association of Dental Laboratories ... campaign to raise awareness among patients about the consequences ...
(Date:4/17/2015)... Jacksonville, Fla. (PRWEB) April 17, 2015 ... Cancer Center have signed a partnership agreement designed to ... , The institutions have agreed to create a ... Anderson’s treatment protocols and translational research. Baptist MD Anderson ... of 2015, providing a single destination for highly coordinated, ...
(Date:4/17/2015)... April 17, 2015 Scientists from ... multicenter team of U.S. and Venezuelan researchers, have ... in humans among an isolated tribe of Yanomami ... Bacterial diversity in the Yanomami, previously unexposed to ... nearly double that of people living in industrialized ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... Fat Pad Restoration on The Balancing Act on Lifetime TelevisionBOCA ... great doing it" is more than a tag line for ... is a leading expert and innovator in the science of ... a woman, she understands the emotional needs that many women ...
... Pharmakon introduced next generation of health ... quality natural liquid calcium & mineral supplement ... segments of athletes, women in pre and ... calcium supplementation. The innovative products of Aim ...
... the HR outsourcing marketplace, Empyrean Benefit Solutions is changing the status ... lower price. , ... Houston, TX (PRWEB) January 12, ... to grow by over 800% in annual revenue in their first ...
... employ comparative effectiveness research tools to address large, unwarranted variations ... benefits corporate spending. , ... Phoenixville, ... effectiveness data addresses large and unwarranted variations in corporate spending. ...
... SAN FRANCISCO, Jan. 12 Hiemstra Product Development, ... the debut of,hiQual, its proprietary electronic quality management ... the integration of hiQual, Hiemstra,s development team can ... the necessary documentation,required under ISO 13485:2003 and FDA ...
... Jan. 12 Acclarent, Inc., a leading,medical technology ... address conditions affecting the ear, nose and,throat, announced ... financing round.,Acclarent intends to use the proceeds to ... as on-going investment in product,development and clinical studies. ...
Cached Medicine News:Health News:Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 3Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 4Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 2Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development 2Health News:Acclarent, Inc. Closes $26 Million Financing 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The Vibratome Roto-Shake Genie is an ... It performs five different mixing ... and rotating/rolling, as well as a ... The precision-engineered moving portion of the ...
... The Vibratome Roto-Shake Genie is ... platform. It performs five different ... rolling/rocking and rotating/rolling, as well as ... The precision-engineered moving portion of ...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Medicine Products: